Cell and Gene Therapies: A Perspective
Cell and gene therapies promise medical breakthroughs, but manufacturing complexity, $2M price tags, and patient journey challenges force major pharma exits.
Market & Economics
Market analysis, pricing, business models
Roche and Alzheimer’s disease
SPECIAL REPORT 25.09
Roche and Alzheimer’s disease
On July 28, at the Alzheimer’s Association International Conference (AAIC) held in Toronto (Canada), Roche presented new data from its development portfolio including additional diagnostics outcomes.
In several oral presentations Roche disclosed its latest results from the ongoing trontinemab’s
Sanofi au plus bas depuis trois ans.
SPECIAL REPORT 25.08
Sanofi au plus bas depuis trois ans.
Chers anciens collègues,
Ancien salarié et dirigeant de Sanofi je reste, comme de nombreux d’entre vous, très attentif à son évolution. Le 31 juillet est à nouveau une journée sombre pour le Groupe puisque le cours de son
Abivax: Ahead of a bright future?
SPECIAL REPORT 25.07
Abivax: Ahead of a bright future?
On Tuesday, July 22, just after the closure of Wall Street, Abivax announced positive phase 3 results for the treatment of ulcerative colitis (UC). The Paris and Boston-based biotechnology company conducted two clinical studies (ABTECT-1 and ABTECT-2 in 8 week
Des chiffres précis
SPECIAL REPORT 25.06
Des chiffres précis
Le Premier Ministre, François Bayrou a promis d’annoncer le budget 2026 de la France, début juillet 2025, mais surtout d’expliciter sa structuration avec un objectif de 40 milliards d’économie. Cette somme en soi importante est à replacer dans un contexte
Targeted protein degradation
SPECIAL REPORT 25.5
Scientific publication
This article was published in a different format in the April issue of MedNous
Learn more
The development of new drugs is dependent on many factors, and one of the most important is being able to identify and reach a target. For years, a
US FDA Novel Drug Approval for 2024.
SPECIAL REPORT 25.1
We wish all our readers and followers a Happy and Prosperous Year 2025
US FDA Novel Drug Approval for 2024.The latest report issued by the FDA’s Center for Drug Evaluation and Research (CDER) indicates that the US health agency has approved 50 novel drugs